Listed biomedical firm Pacific Edge has struck a deal to license its world-first bladder cancer diagnostic test in Spain and Portugal.
The company has signed up the biotechnology and molecular diagnostics company, Oryzon, to market its Cxbladder urine test to urologists and GPs.
Under the agreement, Oryzon will pay an undisclosed upfront fee, as well as royalties and sales payments.
In March, Pacific Edge licensed Healthscope, which owns 44 private hospitals and 48 clinics in Australia, New Zealand and Asia, to use its Cxbladder product.
